标题
Emerging drugs for schizophrenia: an update
作者
关键词
-
出版物
EXPERT OPINION ON EMERGING DRUGS
Volume 19, Issue 4, Pages 511-531
出版商
Informa Healthcare
发表日期
2014-09-19
DOI
10.1517/14728214.2014.958148
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment
- (2014) Celine M. Laffont et al. CLINICAL PHARMACOKINETICS
- The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review
- (2014) J. Peuskens et al. CNS DRUGS
- A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – Results from the CandleLyte study
- (2014) D. Bugarski-Kirola et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- The Endocannabinoid System and Schizophrenia: Links to the Underlying Pathophysiology and to Novel Treatment Approaches
- (2014) Swapnil Gupta et al. JOURNAL OF CLINICAL PSYCHIATRY
- Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders
- (2014) Peng Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitor for the Potential Treatment of Schizophrenia
- (2014) José Manuel Bartolomé-Nebreda et al. JOURNAL OF MEDICINAL CHEMISTRY
- Normalizing Effects of EVP-6124, an Alpha-7 Nicotinic Partial Agonist, on Event-Related Potentials and Cognition
- (2014) SHELDON H. PRESKORN et al. Journal of Psychiatric Practice
- A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia
- (2014) Joan H.Q. Shen et al. JOURNAL OF PSYCHIATRIC RESEARCH
- A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia
- (2014) Clare M. Gibson et al. SCHIZOPHRENIA RESEARCH
- Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options
- (2014) Pierre Chue et al. Neuropsychiatric Disease and Treatment
- Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
- (2014) Daniel Umbricht et al. JAMA Psychiatry
- Bitopertin
- (2014) Donald C. Goff JAMA Psychiatry
- Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review
- (2013) G. Fond et al. ACTA PSYCHIATRICA SCANDINAVICA
- A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia
- (2013) David H Adams et al. BMC Psychiatry
- The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review
- (2013) Domenico De Berardis et al. CNS & Neurological Disorders-Drug Targets
- Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study
- (2013) Margarita A. Morozova et al. CNS SPECTRUMS
- Alternative pharmacologic targets for the treatment of schizophrenia
- (2013) Seiya Miyamoto et al. CURRENT OPINION IN PSYCHIATRY
- Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
- (2013) Kenji Hashimoto et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability
- (2013) Leslie Citrome Expert Opinion on Drug Metabolism & Toxicology
- Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010
- (2013) Harvey A Whiteford et al. LANCET
- Pimavanserin as treatment for Parkinson's disease psychosis
- (2013) Susan H Fox LANCET
- Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain
- (2013) Robert J. Harvey et al. NATURE REVIEWS DRUG DISCOVERY
- Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update
- (2013) I. E. Sommer et al. SCHIZOPHRENIA BULLETIN
- Adjunctive Use of Nonsteroidal Anti-inflammatory Drugs for Schizophrenia: A Meta-analytic Investigation of Randomized Controlled Trials
- (2013) Masahiro Nitta et al. SCHIZOPHRENIA BULLETIN
- Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia
- (2013) Stephen R. Marder et al. SCHIZOPHRENIA RESEARCH
- Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
- (2013) Virginia L. Stauffer et al. SCHIZOPHRENIA RESEARCH
- Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis
- (2013) Kate Merritt et al. Frontiers in Psychiatry
- The Endocannabinoid System and Schizophrenia: Integration of Evidence
- (2012) Erica Zamberletti et al. CURRENT PHARMACEUTICAL DESIGN
- Kann Cannabis das Risiko für schizophrene Psychosen erhöhen?
- (2012) H. Bugra et al. FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
- Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis
- (2012) Jian-Ping Zhang et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Eicosapentaenoic Acid Interventions in Schizophrenia
- (2012) Paolo Fusar-Poli et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010
- (2012) Joshua A Salomon et al. LANCET
- Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
- (2012) S Miyamoto et al. MOLECULAR PSYCHIATRY
- Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
- (2012) Mark J. Millan et al. NATURE REVIEWS DRUG DISCOVERY
- The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey
- (2012) Sean M. Smith et al. NEUROPHARMACOLOGY
- Treating patients with schizophrenia deficit with erythropoietin?
- (2012) Guillaume Fond et al. PSYCHIATRY AND CLINICAL NEUROSCIENCES
- Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day
- (2012) Herbert Y. Meltzer et al. SCHIZOPHRENIA RESEARCH
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- (2012) F M Leweke et al. Translational Psychiatry
- Quantifying Clinical Relevance in the Treatment of Schizophrenia
- (2011) Christoph U. Correll et al. CLINICAL THERAPEUTICS
- Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia
- (2011) Surendra P. Singh et al. CNS DRUGS
- 5-HT6 receptor and cognition
- (2011) Xabier Codony et al. CURRENT OPINION IN PHARMACOLOGY
- PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
- (2011) Jan Kehler et al. CURRENT PHARMACEUTICAL DESIGN
- Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups
- (2011) C.U. Correll et al. EUROPEAN PSYCHIATRY
- Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults
- (2011) Alicia Ruelaz Maher et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics
- (2011) T Kishimoto et al. MOLECULAR PSYCHIATRY
- Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
- (2011) Marc De Hert et al. Nature Reviews Endocrinology
- Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia
- (2011) Carrie K Jones et al. NEUROPSYCHOPHARMACOLOGY
- Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis
- (2011) Eric Michael Hecht et al. SCHIZOPHRENIA RESEARCH
- Therapeutic Potential of 5-HT2CReceptor Ligands
- (2011) Nanna H. Jensen et al. TheScientificWorldJOURNAL
- Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease
- (2010) Colleen M. Niswender et al. Annual Review of Pharmacology and Toxicology
- Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
- (2010) Lawrence S. Kegeles et al. ARCHIVES OF GENERAL PSYCHIATRY
- Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis
- (2010) Surendra P. Singh et al. BRITISH JOURNAL OF PSYCHIATRY
- Cholinesterase Inhibitors as Adjunctive Therapy in Patients with Schizophrenia and Schizoaffective Disorder
- (2010) Salma R.I. Ribeiz et al. CNS DRUGS
- From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics
- (2010) C.U. Correll EUROPEAN PSYCHIATRY
- Past and Present Progress in the Pharmacologic Treatment of Schizophrenia
- (2010) John M. Kane et al. JOURNAL OF CLINICAL PSYCHIATRY
- Rethinking schizophrenia
- (2010) Thomas R. Insel NATURE
- Behandlung kognitiver Defizite bei Schizophrenie
- (2010) D. Roesch-Ely et al. NERVENARZT
- Beta-Blocker Supplementation of Standard Drug Treatment for Schizophrenia
- (2010) E. Shek et al. SCHIZOPHRENIA BULLETIN
- Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons
- (2010) Christine Rummel-Kluge et al. SCHIZOPHRENIA BULLETIN
- Antipsychotic drugs and obesity
- (2010) Christoph U. Correll et al. TRENDS IN MOLECULAR MEDICINE
- Signaling pathways in schizophrenia: emerging targets and therapeutic strategies
- (2010) Caline S. Karam et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Modafinil as an Adjunctive Treatment of Sedation, Negative Symptoms, and Cognition in Schizophrenia
- (2009) Carlos Saavedra-Velez et al. JOURNAL OF CLINICAL PSYCHIATRY
- Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
- (2008) Anantha Shekhar et al. AMERICAN JOURNAL OF PSYCHIATRY
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
- (2008) Stefan Leucht et al. LANCET
- Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
- (2008) J. A. Lieberman et al. PHARMACOLOGICAL REVIEWS
- Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials
- (2008) C. U. Correll et al. SCHIZOPHRENIA BULLETIN
- Cognitive dysfunction in neuropsychiatric disorders: Selected serotonin receptor subtypes as therapeutic targets
- (2007) Alvin V. Terry et al. BEHAVIOURAL BRAIN RESEARCH
- Predicting Schizophrenia Patients’ Real-World Behavior with Specific Neuropsychological and Functional Capacity Measures
- (2007) Christopher R. Bowie et al. BIOLOGICAL PSYCHIATRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More